FOLH1 and prostate cancer: GRPR targeting for the imaging of prostate cancer has been increasingly evaluated in recent years due to the limitations of the well-established PSMA targeting, which include PSMA-negative lesions [24], false-positive scans [25], and a degree of resistance to PSMA-targeted radionuclide therapy [26].